Non-V600E <i>BRAF</i> mutations and treatment for hairy cell leukemiaEvgeny Arons, R. J. Kreitman, Chi‐Ping Day et al.|Blood|2024Cited by 8
Rituximab Reduces Immunogenicity and Increases Complete Remissions without Minimal Residual Disease in Relapsed/Refractory Hairy Cell Leukemia Patients Receiving Moxetumomab PasudotoxR. J. Kreitman, Ira Pastan, Constance M. Yuan et al.|Blood|2024Cited by 1